AMARIN®

Third Quarter 2022 Financial Results and Business Update Conference Call

Karim Mikhail
President & CEO

Tom Reilly
CFO

October 27, 2022

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA®(VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

Karim Mikhail
President & CEO

THIRD QUARTER
2022 HIGHLIGHTS

Amarin Growth Strategy

Total Revenue by Quarter



Third Quarter 2022 Results

OPERATIONAL INITIATIVES RESULTING IN LOWER CASH BURN

- Third quarter 2022 was **CASH POSITIVE** excluding restructuring charges
- Cost reduction plan in June on-track to reduce operating costs by approximately $100 MILLION THROUGH MID-2023
- Efforts to renegotiate supply purchase agreements continue

STABILIZATION OF US REVENUE DRIVES STRONG PERFORMANCE

- Third quarter 2022 total net revenue was $89.9 million including U.S. product revenue of $87.9 million
- Despite ongoing generic competition, the third quarter of 2022 was the **third consecutive quarter of stable revenue trends for VASCEPA in the U.S.**

AMARIN™

Amarin Maintaining 60% + Share in US Market





Significant Market Opportunity

4M deaths per year in Europe WHO region due to CVD[1]

~€210B annual CVD costs to European Union[2]

10+ years of market exclusivity in Europe

1. ESC: Cardiovascular Disease Statistics 2019
2. European Heart Network. European Cardiovascular Disease Statistics 2017. https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html. Accessed January 2022

AMARIN

Europe Progress To Date in 2022:

✓ Achieved national reimbursements in **Sweden, England, Wales, Northern Ireland**, and **Finland** and have obtained individual reimbursement in **Denmark** and **Austria**

✓ Launched in **England and Wales** as planned on October 13, 2022

✓ Also making progress in additional key European markets:

- **Spain:** Pricing & reimbursement negotiations nearing conclusion with Ministry of Health, likely pricing and reimbursement decision before the end of 2022
- **Italy:** Dossier has received positive scientific assessment and moved to pricing and reimbursement negotiations
- **France:** Received positive reimbursement assessment from HAS; price negotiations continue to progress
- **Portugal, Switzerland, Scotland, Israel:** All previously submitted dossiers and progressing pricing and reimbursement negotiations

Continued Progress in Europe: Pricing & Reimbursement Decision and Launch Efforts



AMARIN

*National reimbursement negotiation in process.

**Initial GKV finding no benefit; reimbursement discussions ongoing

International Growth Expansion Through Partnerships Represents Potential $1B Opportunity

Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets

1ST WAVE 2022
UP TO
6
COUNTRIES
Hong Kong, Saudi Arabia, Bahrain Achieved; Additional markets pending including Australia, New Zealand

2ND WAVE 2023
UP TO
9
COUNTRIES

3RD WAVE 2024
UP TO
5
COUNTRIES

Supported by REDUCE-IT Study and U.S. FDA and EMA Filings

AMARIN™

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary market to market.

Continued Presence, Key Data Featured at Global Congresses

AUG
26–29th

ESC Congress 2022
Barcelona
ONSITE & ONLINE, 26-29 AUGUST

OCT
27–30th

CANADIAN CARDIOVASCULAR CONGRESS
October 27–30, 2022

CANADIAN CARDIOVASCULAR SOCIETY · SOCIÉTÉ CANADIENNE DE CARDIOLOGIE
1947-2022

NOV
5–7th

American Heart Association.
Scientific Sessions
November 5-7, 2022
Chicago, IL + Virtual
McCormick Place Convention Center

NOV
6–9th

Progress and Achievements YTD 2022

US BUSINESS DEMONSTRATING ENCOURAGING TRENDS

- Recent stable **prescription** trends based on **previous 14-plus** weeks of trends*
- **Quarterly revenue** remains relatively stable

SIGNIFICANT PROGRESS ON CASH PRESERVATION INITIATIVES

- Cost savings plans to achieve **$100 million** in annual savings by mid-2023 on target
- Renegotiations of supply agreements continue to progress resulting in **reduction of inventory purchases**

EUROPEAN REIMBURSEMENT DISCUSSIONS UNDERWAY

- Additional decisions and progress in major markets anticipated prior to year-end 2022

INTERNATIONAL EXPANSION PLANS ON TRACK

- Regulatory approvals in up to six markets by year-end with partnership activities underway

ONGOING DEVELOPMENT OF SCIENTIFIC EVIDENCE TO SUPPORT VASCEPA/VAZKEPA

- **Strong presence at ESC**, with additional data submissions completed for global Congresses

Tom Reilly
CFO

THIRD QUARTER
FINANCIAL RESULTS

Third Quarter 2022 Financial Highlights

(in millions, except per share amounts)

	Q3 2022	Q2 2022	Q3 2021
Total Net Revenue	$89.9	$94.4	$142.0
Cost of Goods Sold*	$23.9	$26.2	$30.2
Gross Margin (Overall)*	73%	72%	79%
Operating Expenses**	$64.5	$96.3	$110.8
SG&A Expenses	$58.7	$86.9	$103.0
R&D Expenses	$5.8	$9.4	$7.8

	Q3 2022
GAAP Net Loss	$5.1
Basic and Diluted Loss Per Share	$0.01

	September 30, 2022
Aggregate Cash & Investments	$306.0

***Cost of Goods Sold excludes restructuring charges and inventory write-off charges:**

- Q3 2022 - $3.1 M in restructuring charges; reportable Gross Margin was 70%
- Q2 2022 - $15.0M in restructuring and $9.6M in inventory write-off charges, reportable Gross Margin was 46%

****Operating Expenses excludes restructuring charges:**

- Q3 2022 - $3.5M
- Q2 2022 - $10.2M
- Q3 2021 - $14.1M

AMARIN™

Recent Initiatives Result in Lower Operating Expenses and Cash Burn

$ M's



$ M's



AMARIN

** **+$6M** cash flow positive excluding $25M Q2'22 restructuring which was paid in Q3'22*

Karim Mikhail
President & CEO

THIRD QUARTER
CLOSING REMARKS

Upcoming Drivers of Success

OPERATIONAL TRENDS CONTINUE TO IMPROVE CASH POSITION

- Maintaining stabilization of U.S. Business
- Reduce operational spending as outlined in cost savings plan
- Completion of additional cash preservation initiatives to continue to reduce cash burn

GLOBAL EXPANSION PLANS ON TRACK IN MAJOR MARKETS

- Successful VAZKEPA Commercialization start in the UK on 10/13/22
- Potential pricing & reimbursement decisions in additional major EU markets (including Spain, Italy, Netherlands, France)
- Achieve international regulatory approvals in additional countries and further partnership activities

GLOBAL FOCUS ON CONTINUING TO BUILD DATA EVIDENCE

- Continue to generate additional data evidence in support of VASCEPA/VAZKEPA globally
- Maintain active presence at medical meetings including upcoming AHA meeting in November

BOLD AMBITIONS for AMARIN®

Leading a new paradigm in preventive cardiovascular care and growing our impact for patients globally

AMARIN®

Vascepa® (icosapent ethyl)

Vazkepa® (icosapent ethyl)

THANK YOU

Investor Presentation

October 2022